Pharsight

Oxtellar Xr is owned by Supernus Pharms.

Oxtellar Xr contains Oxcarbazepine.

Oxtellar Xr has a total of 10 drug patents out of which 0 drug patents have expired.

Oxtellar Xr was authorised for market use on 19 October, 2012.

Oxtellar Xr is available in tablet, extended release;oral dosage forms.

Oxtellar Xr can be used as treatment of partial-onset seizures.

The generics of Oxtellar Xr are possible to be released after 13 April, 2027.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855278	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US8821930	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US10220042	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9119791	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US7910131	SUPERNUS PHARMS	Method of treating seizures using modified release formulations of oxcarbazepine	Apr, 2027 (3 years from now)
US11166960	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9351975	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US7722898	SUPERNUS PHARMS	Modified-release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US8617600	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9370525	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)